
1. J Clin Oncol. 2021 Nov 24:JCO2102229. doi: 10.1200/JCO.21.02229. [Epub ahead of
print]

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus
Ipilimumab in Patients With Advanced Melanoma.

Wolchok JD(1), Chiarion-Sileni V(2), Gonzalez R(3), Grob JJ(4), Rutkowski P(5),
Lao CD(6), Cowey CL(7), Schadendorf D(8), Wagstaff J(9), Dummer R(10), Ferrucci
PF(11), Smylie M(12), Butler MO(13), Hill A(14), Márquez-Rodas I(15), Haanen
JBAG(16), Guidoboni M(17), Maio M(18), Schöffski P(19), Carlino MS(20), Lebbé
C(21), McArthur G(22), Ascierto PA(23), Daniels GA(24), Long GV(25), Bas T(26),
Ritchings C(26), Larkin J(27), Hodi FS(28).

Author information: 
(1)Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New 
York, NY.
(2)Venteo Institute of Oncology IOV-IRCCS, Padua, Italy.
(3)University of Colorado Cancer Center, Aurora, CO.
(4)Aix-Marseille University, APHM Timone France, Marseille, France.
(5)Maria Sklodowska-Curie National Institute of Oncology Center, Warsaw, Poland.
(6)University of Michigan, Ann Arbor, MI.
(7)Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX.
(8)University of Essen, Essen, and German Cancer Consortium, Heidelberg, Germany.
(9)The College of Medicine, Swansea University, Swansea, United Kingdom.
(10)Universitäts Spital Zürich, Zürich, Switzerland.
(11)European Institute of Oncology IRCCS, Milan, Italy.
(12)Cross Cancer Institute, Edmonton, Alberta, Canada.
(13)Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
(14)Tasman Oncology Research, Southport, Queensland, Australia.
(15)Hospital General Universitario Gregorio Marañon, Madrid, Spain.
(16)Netherlands Cancer Institute, Amsterdam, the Netherlands.
(17)Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS,
Meldola, Italy.
(18)Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy.
(19)University Hospitals Leuven, Department of General Medical Oncology, Leuven
Cancer Institute, KU Leuven, Leuven, Belgium.
(20)Westmead and Blacktown Hospitals, University of Sydney, Melanoma Institute
Australia, Sydney, Australia.
(21)Université de Paris, Department of Dermatology and CIC, AP-HP Hôpital Saint
Louis, INSERM U976, Paris, France.
(22)Peter MacCallum Cancer Centre, East Melbourne, Australia.
(23)Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale
Tumori IRCCS Fondazione Pascale, Napoli, Italy.
(24)UC San Diego Health - La Jolla, La Jolla, CA.
(25)Melanoma Institute Australia, The University of Sydney, and Royal North Shore
and Mater Hospitals, Sydney, Australia.
(26)Bristol Myers Squibb, Princeton, NJ.
(27)The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
(28)Dana-Farber Cancer Institute, Boston, MA.

PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was
demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus
ipilimumab. Here, we report 6.5-year efficacy and safety outcomes.
PATIENTS AND METHODS: Patients with previously untreated unresectable stage III
or stage IV melanoma were randomly assigned 1:1:1 to receive nivolumab 1 mg/kg
plus ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by nivolumab 3
mg/kg once every 2 weeks (n = 314), nivolumab 3 mg/kg once every 2 weeks (n =
316), or ipilimumab 3 mg/kg once every 3 weeks (four doses; n = 315). Coprimary
end points were progression-free survival and overall survival (OS) with
nivolumab plus ipilimumab or nivolumab versus ipilimumab. Secondary end points
included objective response rate, descriptive efficacy assessments of nivolumab
plus ipilimumab versus nivolumab alone, and safety. Melanoma-specific survival
(MSS; descriptive analysis), which excludes deaths unrelated to melanoma, was
also evaluated.
RESULTS: Median OS (minimum follow-up, 6.5 years) was 72.1, 36.9, and 19.9 months
in the combination, nivolumab, and ipilimumab groups, respectively. Median MSS
was not reached, 58.7, and 21.9 months, respectively; 6.5-year OS rates were 57%,
43%, and 25% in patients with BRAF-mutant tumors and 46%, 42%, and 22% in those
with BRAF-wild-type tumors, respectively. In patients who discontinued treatment,
the median treatment-free interval was 27.6, 2.3, and 1.9 months, respectively.
Since the 5-year analysis, no new safety signals were observed.
CONCLUSION: These 6.5-year CheckMate 067 results, which include the longest
median OS in a phase III melanoma trial reported to date and the first report of 
MSS, showed durable, improved clinical outcomes with nivolumab plus ipilimumab or
nivolumab versus ipilimumab in patients with advanced melanoma and, in
descriptive analyses, with the combination over nivolumab monotherapy.

DOI: 10.1200/JCO.21.02229 
PMID: 34818112 

Conflict of interest statement: Jedd D. WolchokStock and Other Ownership
Interests: Tizona Therapeutics Inc, Adaptive Biotechnologies, Imvaq Therapeutics,
Beigene, Linnaeus Therapeutics, Arsenal IO, Georgiamune, LLC, Apricity
Therapeutics, Maverick Therapeutics, Trieza TherapeuticsConsulting or Advisory
Role: Bristol Myers Squibb, Merck, Sellas Life Sciences, Lilly, Tizona
Therapeutics, Inc, Amgen, Chugai Pharma, Adaptive Biotechnologies, Ascentage
Pharma, PsiOxus Therapeutics, F-Star Biotechnology, Surface Oncology, Apricity
Therapeutics, Astellas Pharma, Recepta Biopharma, Arsenal IO, Boehringer
Ingelheim, AstraZeneca, Daiichi Sankyo, IncDragonfly Therapeutics, Georgiamune,
Kyowa Kirin Pharmaceutical, Maverick Therapeutics, Werewolf Therapeutics,
Trishula Therapeutics, Idera, Imvaq Therapeutics, Bicara TherapeuticsResearch
Funding: Bristol Myers Squibb (Inst), Genentech/Roche (Inst), Merck Sharp & Dohme
(Inst)Patents, Royalties, Other Intellectual Property: I am a coinventor on an
issued patent for DNA vaccines for treatment of cancer in companion animals. I am
a coinventor on a patent for use of oncolytic Newcastle Disease virus. I am a
coinventor and receive royalties for a blood test for monitoring myeloid derived 
suppressor cells. I am coinventor and receive royalties for a patent for immune
modulating antibodies. I am a coinventor on a patent for CAR+ T cells targeting
differentiation antigens as means to treat cancer. I am a coinventor on a patent 
for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer
therapy. Alphavirus replicon particles expressing TRP2. Engineered Vaccinia
Viruses for Cancer Immunotherapy. Recombinant poxviruses for cancer immunotherapy
Vanna Chiarion-SileniConsulting or Advisory Role: MSD Oncology, Merck Serono,
Bristol Myers Squibb, Novartis, Pierre Fabre, RocheSpeakers' Bureau: Bristol
Myers Squibb, Novartis, Merck Serono, Pierre FabreTravel, Accommodations,
Expenses: Bristol Myers Squibb, Pierre Fabre Rene GonzalezStock and Other
Ownership Interests: AstraZeneca, GlaxoSmithKline, Lilly, Johnson & Johnson,
Merck, Novartis, Pfizer, Procter & Gamble, SanofiConsulting or Advisory Role:
AmgenResearch Funding: Millenium Pharamceuticals (Inst), Takeda (Inst), Boston
Biomedical (Inst), Bristol Myers Squibb (Inst), Checkmate Pharmaceuticals (Inst),
Incyte (Inst), Syndax (Inst), Roche/Genentech (Inst), Tesaro (Inst), Amgen
(Inst), Morphotek (Inst), Checkmate Pharmaceuticals (Inst), Regeneron (Inst),
Iovance Biotherapeutics (Inst), Nektar (Inst), Kartos Therapeutics (Inst), Taiga 
(Inst), Incyte (Inst), Exicure (Inst), Replimune (Inst), Alkermes (Inst),
Ultimovacs (Inst), Moderna Therapeutics (Inst), OncoSec¸ Synlogic (Inst), Merck
(Inst), Array BioPharma (Inst), Senhwa Biosciences (Inst), Immunocore (Inst), EMD
Serono (Inst) Jean-Jacques GrobConsulting or Advisory Role: BMS, MSD Oncology,
Roche/Genentech, Novartis, Amgen, Pierre Fabre, Sun Pharma, Merck KGaA, Sanofi,
Pfizer, RocheSpeakers' Bureau: NovartisTravel, Accommodations, Expenses: BMS, MSD
Oncology, Novartis, Pierre Fabre Piotr RutkowskiHonoraria: Bristol Myers Squibb, 
MSD, Novartis, Roche, Lilly, Pfizer, Pierre Fabre, Sanofi, MerckConsulting or
Advisory Role: Novartis, Blueprint Medicines, Bristol Myers Squibb, Pierre Fabre,
MSD, AmgenSpeakers' Bureau: Pfizer, Novartis, LillyResearch Funding: Novartis
(Inst), Roche (Inst), Bristol Myers Squibb (Inst)Travel, Accommodations,
Expenses: Orphan Europe, Pierre Fabre Christopher D. LaoConsulting or Advisory
Role: Immunocore, BMSResearch Funding: Bristol Myers Squibb, Dynavax
Technologies, GenentechTravel, Accommodations, Expenses: Immunocore, BMS C. Lance
CoweyEmployment: Texas Oncology, US OncologyLeadership: US OncologyHonoraria:
MerckConsulting or Advisory Role: Merck, Novartis, Pfizer¸ Iovance
BiotherapeuticsResearch Funding: Bristol Myers Squibb (Inst), Genentech/Roche
(Inst), Novartis (Inst), EMD Serono (Inst), Merck (Inst), Array BioPharma (Inst),
Amgen (Inst), Regeneron (Inst), Celldex (Inst), Seattle Genetics (Inst) Dirk
SchadendorfHonoraria: Roche/Genentech, Novartis, Bristol Myers Squibb, Merck
Sharp & Dohme, Immunocore, Merck Serono, Array BioPharma, Pfizer, Pierre Fabre,
Philogen, Regeneron, 4SC, Sanofi/Regeneron, NeraCare GmbH, Sun Pharma,
InflarxGmbH, Ultimovacs, SandozConsulting or Advisory Role: Roche/Genentech,
Novartis, Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, 4SC, Pierre
Fabre, Sanofi/Regeneron, NektarSpeakers' Bureau: Bristol Myers Squibb, Merck
Sharp & Dohme, Novartis, Pierre Fabre, Sanofi/Regeneron, Merck KGaAResearch
Funding: Bristol Myers Squibb (Inst), Novartis (Inst), Roche (Inst), MSD Oncology
(Inst), Array BioPharma/Pfizer (Inst)Travel, Accommodations, Expenses:
Roche/Genentech, Bristol Myers Squibb, Merck Serono, Novartis, Merck Sharp &
Dohme, Pierre Fabre, Sanofi/Regeneron John WagstaffHonoraria: Bristol Myers
Squibb, Roche, Pierre Fabre, Novartis, GlaxoSmithKline UK Ltd, PfizerConsulting
or Advisory Role: Bristol Myers Squibb, Roche, Pfizer, Novartis, Pierre
FabreSpeakers' Bureau: Bristol Myers Squibb Reinhard DummerHonoraria: Roche,
Novartis, Bristol Myers Squibb, MSD, Amgen, Takeda, Pierre Fabre, Sun Pharma,
Sanofi, Catalym, Second Genome, Regeneron, Alligator Bioscience, MaxiVax,
touchIME, T3 Pharmaceuticals, PfizerConsulting or Advisory Role: Roche, Bristol
Myers Squibb, MSD, Novartis, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi,
Catalym, Second Genome, Alligator Bioscience, touchIME, MaxiVax, Regeneron,
Pfizer, T3 PharmaceuticalsResearch Funding: Roche (Inst), Bristol Myers Squibb
(Inst), Novartis (Inst), MSD (Inst), Amgen (Inst) Pier Francesco
FerrucciConsulting or Advisory Role: Bristol Myers Squibb, Roche, Novartis, MSD
Oncology, Pierre FabreResearch Funding: BMSTravel, Accommodations, Expenses: MSD 
Oncology, Bristol Myers Squibb Michael SmylieHonoraria: Bristol Myers Squibb,
Novartis Canada Pharmaceuticals Inc, Merck, Roche Canada,
Sanofi/RegeneronConsulting or Advisory Role: Merck Marcus O. ButlerHonoraria:
Merck, Roche, Bristol Myers Squibb, NovartisConsulting or Advisory Role: Merck,
Bristol Myers Squibb, Novartis, Immunovaccine, Immunocore, Adaptimmune, EMD
Serono, GlaxoSmithKline, Genzyme, Sanofi, LaRoche Posay, Sun Pharma, Instil Bio, 
Iovance Biotherapeutics, Pfizer, AdaptimmuneResearch Funding: Merck, Takara
BioExpert Testimony: Merck Andrew HillEmployment: Tasman OncologyStock and Other 
Ownership Interests: Tasman Oncology Ivan Márquez-RodasConsulting or Advisory
Role: Bristol Myers Squibb, MSD¸ Novartis, Roche, Amgen, Sanofi, AstraZeneca,
Merck Serono, Incyte, Bioncotech, Pierre Fabre, RegeneronTravel, Accommodations, 
Expenses: Bristol Myers Squibb, MSD¸ Roche, Bioncotech John B. A. G. HaanenStock 
and Other Ownership Interests: Neogene TherapeuticsConsulting or Advisory Role:
MSD Oncology (Inst), Pfizer (Inst), Bristol Myers Squibb (Inst), Novartis (Inst),
Roche/Genentech (Inst), Ipsen (Inst), Achilles Therapeutics (Inst), Immunocore
(Inst), Sanofi (Inst), Third Rock Ventures (Inst), Neogene Therapeutics (Inst),
Molecular Partners (Inst), bioNTech (Inst), T-Knife (Inst), PokeAcel (Inst),
Instil Bio (Inst), Iovance Biotherapeutics (Inst)Research Funding: MSD (Inst),
Bristol-Myers Squibb (Inst), Novartis (Inst), Neon Therapeutics (Inst), Amgen
(Inst), BioNTech (Inst), Asher Biotherapeutics (Inst) Massimo GuidoboniConsulting
or Advisory Role: BMS, Novartis, Pierre FabreSpeakers' Bureau: BMS, Novartis,
Pierre FabreResearch Funding: MSD Michele MaioStock and Other Ownership
Interests: Theravance, Epigen TherapeuticsHonoraria: Bristol Myers Squibb,
AstraZeneca, Roche, MSD, Merck, Amgen, Pierre Fabre¸ Alfasigma, Sanofi,
LillyConsulting or Advisory Role: Bristol Myers Squibb, Roche, AstraZeneca, MSD, 
Merck, Pierre Fabre, AlfasigmaPatents, Royalties, Other Intellectual Property:
DNA Hypomethylating agents for cancer therapyTravel, Accommodations, Expenses:
Bristol Myers Squibb, AstraZeneca, Roche, MSD, Merck, Amgen, Pierre Fabre,
Alfasigma Patrick SchöffskiHonoraria: Deciphera, Blueprint Medicines, Boehringer 
IngelheimConsulting or Advisory Role: Blueprint Medicines, Ellipses Pharma,
Adaptimmune, Intellisphere, Transgene, Deciphera, Exelixis, Boehringer Ingelheim,
Medscape, Guided Clarity, Ysios Capital, Studiecentrum voor Kernenergie, Modus
Outcomes, Advance Medical/Teladoc Health (Inst), Curio Science, SQZ
Biotechnology, CRT Pioneer Fund LP, AdcendoResearch Funding: CoBioRes NV (Inst), 
Eisai (Inst), G1 Therapeutics (Inst), Novartis (Inst), PharmaMar (Inst)Travel,
Accommodations, Expenses: MSD (Inst), Ipsen (Inst), Boehringer Ingelheim (Inst)
Matteo S. CarlinoHonoraria: Bristol Myers Squibb, MSD, NovartisConsulting or
Advisory Role: Bristol Myers Squibb, MSD, Amgen, Novartis, Pierre Fabre, Roche,
IDEAYA Biosciences, Sanofi, Merck Serono, Regeneron, QBiotics, Nektar, Eisai,
OncoSec Céleste LebbéHonoraria: Roche, Bristol Myers Squibb, Novartis, Amgen,
MSD, Pierre Fabre, Pfizer, IncyteConsulting or Advisory Role: Bristol Myers
Squibb, MSD, Novartis, Amgen, Roche, Merck Serono, Sanofi, Pierre FabreSpeakers' 
Bureau: Roche, Bristol Myers Squibb, Novartis, Amgen, MSDResearch Funding: Roche 
(Inst), Bristol Myers Squibb (Inst)Travel, Accommodations, Expenses: Bristol
Myers Squibb, MSD, Novartis, Sanofi, Pierre FabreOther Relationship: Avantis
Medical Systems Grant McArthurResearch Funding: Genentech/Roche (Inst), MSD
(Inst), Roche (Inst) Paolo A. AsciertoStock and Other Ownership Interests:
PrimeVaxConsulting or Advisory Role: Bristol Myers Squibb, Roche/Genentech, Merck
Sharp & Dohme, Novartis, Array BioPharma, Merck Serono, Pierre Fabre, Incyte,
MedImmune, AstraZeneca¸ Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz,
Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer Ingelheim, Eisai,
Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Takis Biotech, Lunaphore
Technologies, Seattle Genetics, ITeos Therapeutics,Research Funding: Bristol
Myers Squibb (Inst), Roche/Genentech (Inst), Array BioPharma (Inst), Sanofi
(Inst)Travel, Accommodations, Expenses: Merck Sharp & Dohme Gregory A.
DanielsHonoraria: Sanofi/RegeneronConsulting or Advisory Role:
Sanofi/RegeneronSpeakers' Bureau: Regeneron, Array BioPharma,
Sanofi/Regeneron,Research Funding: Bristol Myers Squibb (Inst), Amgen (Inst),
Viralytics (Inst), Nektar (Inst), Merck (Inst) Georgina V. LongHonoraria: BMS,
Pierre FabreConsulting or Advisory Role: Aduro Biotech, Amgen, Boehringer
Ingelheim, Bristol Myers Squibb, Hexal, Highlight Therapeutics, Merck Sharpe &
Dohme, Novartis, OncoSec, Pierre Fabre, QBiotics, Regeneron, SkylineDx,
Specialised Therapeutics, Array BioPharma, Evaxion Biotech A/S Tuba
BasEmployment: Bristol Myers Squibb (I), Merck, Fiore Healthcare Advisors
(I)Stock and Other Ownership Interests: Merck Sharp & Dohme, Bristol Myers Squibb
(I)Consulting or Advisory Role: Fiore Healthcare Advisors (I)Travel,
Accommodations, Expenses: Merck Sharp & Dohme, Fiore Healthcare Advisors (I)
Corey RitchingsEmployment: Bristol Myers SquibbStock and Other Ownership
Interests: Bristol Myers Squibb James LarkinHonoraria: Bristol Myers Squibb,
GlaxoSmithKline, Pfizer, Novartis, Roche/Genentech, Incyte, iOnctura, Merck
Serono, Eisai, Dynavax Technologies, Cancer Research UK, touchIME,
touchEXPERTSConsulting or Advisory Role: Bristol Myers Squibb, GlaxoSmithKline,
Pfizer, Novartis, Boston Biomedical, Incyte, iOnctura, Iovance Biotherapeutics,
Immunocore, YKT Corporation, Apple Tree PartnersResearch Funding: Pfizer (Inst), 
Novartis (Inst), MSD (Inst), Bristol Myers Squibb (Inst), Achilles Therapeutics
(Inst), Roche (Inst), Nektar (Inst), Covance (Inst), Immunocore (Inst), AVEO
(Inst), Pharmacyclics (Inst)Travel, Accommodations, Expenses: Bristol Myers
Squibb, Pfizer, Novartis, Roche/Genentech, AstraZeneca, Incyte, GlaxoSmithKline, 
Pierre Fabre, Merck Serono, iOnctura, British Uro-Oncology Group (BUG), ESMO,
National Cancer Research Institute (NCRI), EUSA Pharma, Syneos Health, Kidney
Cancer Association, Bioevents, MedConcept, RV Mais F. Stephen HodiEmployment:
Dana-Farber Cancer InstituteLeadership: Bicara TherapeuticsStock and Other
Ownership Interests: Apricity Health, Torque, Pionyr, Bicara
TherapeuticsConsulting or Advisory Role: Merck Sharp & Dohme, Novartis,
Genentech/Roche, EMD Serono, Sanofi, Bristol Myers Squibb, Surface Oncology,
Compass Therapeutics, Partners Therapeutics, Pionyr, Torque, Rheos Medicines,
Boston Pharmaceuticals, Checkpoint Therapeutics, Eisai, Bioentre, Gossamer Bio,
Iovance Biotherapeutics, Trillium Therapeutics, Catalym¸ Amgen,
Immunocore,Research Funding: Bristol Myers Squibb (Inst), Merck Sharp & Dohme,
Genentech/Roche, Novartis,Patents, Royalties, Other Intellectual Property: Patent
pending as per institutional policy. Patent pending royalties received on
MICA-related disorders application to institution per institutional IP policy.
Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response.
Compositions and Methods for Identification, Assessment, Prevention, and
Treatment of Melanoma using PD-L1 Isoforms. Methods of Using Pembrolizumab and
TrebananibTravel, Accommodations, Expenses: Novartis, Bristol Myers SquibbOther
Relationship: Bristol Myers Squibb, Genentech/RocheNo other potential conflicts
of interest were reported.

